We Are This Close to "Designer Babies"
By Nina Liss-Schultz,
Mother Jones
| 02. 08. 2016
[cites CGS' Marcy Darnovsky]
Untitled Document
On February 1, scientists from the United Kingdom's Francis Crick Institute got the okay to start research on human embryos using a new genome editing technology called CRISPR. Their work, which will mark only the second time CRISPR has been applied to humans, will use embryos to try to understand the very early stages of human development and pinpoint the genes causing miscarriages and fetal defects.
Not surprisingly, the Crick project has reignited a firestorm of debate over the ethics of human gene editing. "This is the first step in a well mapped-out process heading to genetically modified babies, and a future of consumer eugenics," said Dr. David King, director of Human Genetics Alert, in response to the news.
CRISPR is essentially a cellular scalpel. The small enzyme works by moving through the body's cells and cutting away at precise pieces of the genome—something that's never before been possible to do with such efficiency and ease. Since 2012, it's been used to cut out the gene mutations leading to HIV and sickle cell anemia. Last spring...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...